Zanubrutinib plus Venetoclax in High-Risk CLL
Susan O'Brien, MD, and Nitin Jain, MD discuss highlights in CLL from the EHA2024 meeting. In this video they review the preliminary results in patients with del(17p) and/or TP53 mutation who received zanu + ven combination treatment in the .
